Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE and next-generation, highly selective ...

The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...

University of New Mexico researchers found that the immune enzyme OTULIN drives tau production, brain inflammation and aging.

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...

A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially ...

A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...